Rchr
J-GLOBAL ID：201801009645370134   Update date: Jul. 30, 2024

Kazuhiro Morishita

モリシタ カズヒロ | Kazuhiro Morishita
Affiliation and department：
University of Miyazaki Faculty of Medicine

About University of Miyazaki Faculty of Medicine


Homepage URL  (1)： http://www.med.miyazaki-u.ac.jp/home/biochem1/
Research field  (7)： Tumor diagnostics and therapeutics ,  Virology ,  Medical biochemistry ,  Hematology and oncology ,  Genomics ,  Pathobiochemistry ,  Tumor biology
Research keywords  (7)： 抗体療法 ,  成人T細胞白血病 ,  HTLV-1 ,  レトロウイルス ,  ゲノム解析 ,  リンパ腫 ,  白血病
Papers (242)：
  • Tomonaga Ichikawa, Akira Suekane, Shingo Nakahata, Hidekatsu Iha, Kazuya Shimoda, Takashi Murakami, Kazuhiro Morishita. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma. International journal of molecular sciences. 2024. 25. 5
  • Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, et al. IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors. Frontiers in Oncology. 2024. 13
  • Kosuke Mochida, Shingo Nakahata, Yutaka Suzuki, Kentaro Inoue, Sayaka Moriguchi, Atsushi Yamashita, Masahiro Amano, Kazuhiro Morishita. Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations. Journal of Dermatological Science. 2023
  • Akira Suekane, Tomonaga Ichikawa, Yusuke Saito, Shingo Nakahata, Kazuhiro Morishita. The CGRP Receptor Antagonist MK0974 Induces EVI1high AML Cell Apoptosis by Disrupting ERK Signaling. Anticancer research. 2022. 42. 10. 4743-4752
  • Happy Kurnia Permatasari, Shingo Nakahata, Tomonaga Ichikawa, Yanuar Rahmat Fauzi, Hiroshi Kiyonari, Kotaro Shide, Takuro Kameda, Kazuya Shimoda, Masaya Ono, Tomohiko Taki, et al. Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. Experimental Hematology. 2022. 111. 41-49
ｍore...
MISC (52)：
  • 森下和広, 菅本和寛, 下田和哉, 中武彩子, 阪本訓代, 市川朝永, 松浦靖, 國武久登. ブルーベリー葉抽出液に含まれるプロアントシアニジンを用いた成人T細胞白血病(ATL)予防的治療法の開発. 日本HTLV-1学会学術集会. 2021. 7th
  • 市川朝永, 中畑新吾, 尾野雅哉, 伊波英克, 森下和広. アルギニンメチル基転移酵素PEMT5の活性化はHSP90Aのアルギニンメチル化を介して腫瘍形成を促進する. 日本生化学会大会(Web). 2020. 93rd
  • Tianyuan Hu, Kiyomi Morita, Matthew C Hill, Yajian Jiang, Ayumi Kitano, Yusuke Saito, Feng Wang, Xizeng Mao, Kevin A Hoegenauer, Kazuhiro Morishita, et al. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells. Blood. 2019. 134. 7. 614-625
  • 中畑新吾, SARKAR Bidhan, 西片一郎, 市川朝永, 藤井雅寛, 伊波英克, 森下和広. 成人T細胞白血病リンパ腫においてp47発現低下によるNF-κB経路の活性化はCADM1の高発現を誘導する. 日本分子生物学会年会プログラム・要旨集(Web). 2019. 42nd
  • 中畑 新吾, 下崎 俊介, 市川 朝永, 亀田 拓郎, 日高 智徳, 久冨木 庸子, 黒澤 仁, 下田 和哉, 森下 和広. トランスフェリン受容体抗体はモガムリズマブ治療難治性のATLLの増殖抑制に有効である(High efficacy of anti-TFR1 antibody against the growth of mogamulizmab-resistant ATLL cells). 臨床血液. 2018. 59. 9. 1719-1719
ｍore...
Patents (33)：
ｍore...
Education (1)：
  • 1974 - 1980 University of Tsukuba
Professional career (1)：
  • 医学博士 (東京大学)
Work history (6)：
  • 2004/04 - 現在 University of Miyazaki Faculty of Medicine
  • 2000/04 - 2003/03 Miyazaki Medical College
  • 1992/10 - 2000/03 国立がん研究センター研究所 生物学部 主任研究員、室長
  • 1988/08 - 1992/09 St Jude Children's Research Hospital, Department of Biology Research fellow, Faculty member
  • 1987/01 - 1988/07 Frederick National Cancer Institute, T-cell leukemogenesis section,
Show all
Awards (1)：
  • 2006/07 - 日本白血病基金 クレディセゾン賞
Association Membership(s) (5)：
日本フォスファターゼ学会 ,  THE MOLECULAR BIOLOGY SOCIETY OF JAPAN ,  THE JAPANESE BIOCHEMICAL SOCIETY ,  THE JAPANESE SOCIETY OF HEMATOLOGY ,  THE JAPANESE CANCER ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM